Biological Imaging Guided Antalgic Radiotherapy of Bone Metastases (Phase II Trial)

Biological Imaging Guided Antalgic Radiotherapy of Bone Metastases (Phase II Trial)

Highly selective irradiation requires accurate target definition by high-resolution three-dimensional imaging. Co-registration of FDG-PET and high-resolution CT might be the imaging modality of choice. This choice might target radiation therapy precisely to the intra-osseous volume that is responsible for pain and to spare selectively healthy bone in the vicinity of the metastasis. This strategy could result in equal anti-pain efficacy as conventional large volume radiotherapy, but could allow bone remodeling and preservation of bone structural strength in the vicinity and could lead to reduced toxicity to neighboring organs.

Inclusion Criteria:

• Painful bone metastasis of solid tumors
• A maximum number of bone metastases less or equal to 3
• Life expectancy > 6 months
• Minimum age 21 years
• Signed informed consent

Exclusion Criteria:

• Previous radiotherapy to the painful site
• Bone metastasis from malignant melanoma or renal cell carcinoma
• Associated fracture or extra-osseous component